Authors

  • Исматова К.А., Амонов Ш.Э., Шахобов А.Б.

Keywords:

хронический риносинусит с носовыми полипами, FESS, левоцетиризин, монтелукаст, послеоперационное лечение, рецидив.

References

Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58(Suppl S29):1–464.

Bachert C, Marple B, Schlosser RJ, Hopkins C, Schleimer RP, Lambrecht BN, Bröker BM, Laidlaw T, Song WJ. Adult chronic rhinosinusitis. Nat Rev Dis Primers. 2020 Oct 29;6(1):86. doi: 10.1038/s41572-020-00218-1. PMID: 33122665.

DeConde AS, Soler ZM. Chronic rhinosinusitis: epidemiology and burden of disease. Am J Rhinol Allergy. 2016;30(2):134–139.

Stammberger H, Hawke M. Functional endoscopic sinus surgery: the Messerklinger technique. Otolaryngol Head Neck Surg. 2017;156(2):213–220.

Rudmik L, Smith TL. Quality of life in patients with chronic rhinosinusitis. Curr Allergy Asthma Rep. 2019;19(4):18.

Hopkins C, Browne JP, Slack R, Lund VJ, Brown P. The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict? Otolaryngol Head Neck Surg. 2017;156 (1):24–31.

Hellings PW, Akdis CA, Bachert C. Mechanisms of inflammation in chronic rhinosinusitis. J Allergy Clin Immunol. 2017;140(6):1499–1508.

Canonica GW, Blaiss M. Antihistaminic, anti-inflammatory, and antiallergic properties of the nonsedating second-generation antihistamine desloratadine: a review of the evidence. World Allergy Organ J. 2011 Feb;4(2):47-53. doi: 10.1097/WOX. 0b013e3182093e19. Epub 2011 Feb 23. PMID: 232 68457; PMCID: PMC3500039.

Montuschi, P. Role of Leukotrienes and Leukotriene Modifiers in Asthma. Pharmaceuticals 2010, 3, 1792-1811. https://doi.org/10.3390/ph30 61792

Steinke JW, Borish L. Factors driving nasal polyp formation. Clin Rev Allergy Immunol. 2017;54 (3):308–316.

Kennedy DW. Prognostic factors, outcomes, and staging in ethmoid sinus surgery. Laryngoscope. 2018;128(2):E1–E8.

Smith TL, Kern RC, Palmer JN, Schlosser RJ. Medical therapy vs surgery for chronic rhinosinusitis. Otolaryngol Clin North Am. 2019;52(1):1–15.

Simons FER, Simons KJ. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol. 2016;138(6):1451–1456.

Ciprandi G, Cirillo I. Levocetirizine: anti-inflammatory properties. Clin Exp Allergy. 2017;47(5): 653–660.

Bousquet J, Schünemann HJ, Togias A, Erhola M, Hellings PW, Zuberbier T, et al. Next-generation ARIA care pathways. World Allergy Organ J. 20 18;11(1):8.

Barnes P. J. Cellular and molecular mechanisms of asthma and COPD //Clinical science. – 2017. – Т. 131. – №. 13. – С. 1541-1558.

Wilson AM, Orr LC, Sims EJ, Lipworth BJ. Effects of montelukast in nasal polyposis. J Allergy Clin Immunol. 2016;138(5):1436–1439.

Kieff DA, Busaba NY. The role of leukotriene inhibitors in chronic rhinosinusitis. Laryngoscope. 2017;127(6):1352–1357.

Van Gerven L, Boeckxstaens G, Jorissen M, Hellings PW. Lack of long-term add-on effect by montelukast in postoperative chronic rhinosinusitis with nasal polyps. Laryngoscope. 2018;128(8):1743–1 751.

Head K, Chong LY, Hopkins C, Philpott C, Schilder AG. Short-course oral steroids alone for chronic rhinosinusitis. Cochrane Database Syst Rev. 2016;4:CD011991.

Meltzer EO, Ratner P, Bachert C, Carr W, Berger W. Clinically relevant effect of combined antihistamine and leukotriene receptor antagonist therapy. Ann Allergy Asthma Immunol. 2019;123(3): 240–247.

LaForce C, Prenner BM, Lumry WR. Efficacy of combined therapy with antihistamines and montelukast. Allergy Asthma Proc. 2017;38(2):142–149.

Bender BG, Oppenheimer J. Combined allergic rhinitis therapy: real-world outcomes. J Allergy Clin Immunol Pract. 2018;6(5):1569–1575.

Kim DK, Eun KM, Kim MK, Cho D, Han SA, Han DH, et al. Predictive biomarkers of chronic rhinosinusitis with nasal polyps. Allergy Asthma Immunol Res. 2020;12(5):806–817.

Lee JY, Byun JY, Kim SW. Adjunctive therapy after FESS in chronic rhinosinusitis. Auris Nasus Larynx. 2018;45(3):536–542.

Hox V, Delrue S, Scheers H, Adams E, Keirsbilck S, Jorissen M, et al. Benefits of leukotriene receptor antagonists in selected CRS patients. Allergy. 2019;74(7):1284–1292.

Tan BK, Li QZ, Suh L, Kato A, Conley DB, Chandra RK, et al. Evidence for intranasal inflammation in chronic rhinosinusitis. JAMA Otolaryngol Head Neck Surg. 2020;146(5):459–466.

Cho SH, Kim DW, Gevaert P. Chronic rhinosinusitis with nasal polyps: therapeutic implications. Clin Exp Otorhinolaryngol. 2021;14(1):1–11.

Philip G, Hustad CM, Noonan G, Malice MP, Ezekowitz A, Reiss TF. Reports of adverse events with montelukast. Clin Ther. 2017; 39(6):1115–1125.

https://www.fda.gov/drugs/fdarequires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug

Wang X, Zhang N, Bo M, Holtappels G, Zheng M, Lou H, et al. Diversity of inflammatory endotypes in chronic rhinosinusitis. Rhinology. 2021; 59(2):125–133.

Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W, Hellings P, Brusselle G, De Bacquer D, van Cauwenberge P, Bachert C. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013 Jan;131(1):110-6.e1. doi: 10.1016/j.jaci. 2012.07.047. Epub 2013 Sep 27. PMID: 23021878.

Laidlaw TM, Mullol J, Fan C, Zhang D, Amin N, Khan A. Dupilumab improves upper airway disease. J Allergy Clin Immunol. 2019;143(2):698–707.

Kowalski ML, Agache I, Bavbek S, Bakirtas A, Blanca M, Bochenek G, et al. Diagnosis and management of NSAID-exacerbated respiratory disease. Allergy. 2018;74(1):28–39.

Akdis CA, Arkwright PD, Brüggen MC, Busse W, Gadina M, Guttman-Yassky E, et al. Type 2 immunity in disease. Nat Rev Immunol. 2021;21(1): 21–36.